Navigation Links
CV Therapeutics' Board of Directors Rejects Astellas Unsolicited Proposal
Date:2/20/2009

PALO ALTO, Calif., Feb. 20 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) today announced that its board of directors has thoroughly reviewed and rejected the previously announced unsolicited proposal from Astellas Pharma Inc. to acquire CV Therapeutics at a price of $16.00 per share.

After careful consideration of the proposal with its independent financial and legal advisors, the CV Therapeutics board concluded that the Astellas proposal significantly undervalues the company and is not in the best interests of CV Therapeutics and its stockholders. The board had previously rejected the same proposal on November 21, 2008, when Astellas approached the company privately.

"CV Therapeutics has a strategic plan in place which we believe will enhance shareholder value. Moreover, we have always been, and remain, receptive to opportunities to further enhance shareholder value. Executing on our strategic plan enabled us to achieve outstanding results in 2008, with multiple regulatory approvals, record revenues and two exceptional strategic transactions. This strong record of product approvals, which exceeds that of many pharma companies over the last several years, has allowed the company to establish a solid cash position. The full promotional launch of the improved U.S. Ranexa labeling is just beginning, the introduction of Ranexa in Europe is imminent, and Lexiscan is showing real growth in the marketplace. Accordingly, we expect 2009 to be another outstanding year, highlighted by increasing revenues and pipeline advancement, for example with CVT-3619," said Louis G. Lange, chairman and chief executive officer of CV Therapeutics.


    Following is the text of the letter being sent by CV Therapeutics today
    to Masafumi Nogimori, president and chief executive officer of Astellas
    Pharma:

 
'/>"/>
SOURCE  CV Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 

Related biology technology :

1. CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results
2. Sopherion Therapeutics Secures $55 Million in Series C Funding
3. Amicus Therapeutics Announces Change to Board of Directors
4. Opsona Therapeutics Closes EUR18M Funding
5. Sirion Therapeutics Partners With Advanced Vision Research (TheraTears(R)) to Promote Products for Retinal and Meibomian Gland Health
6. First Multiple Dose Clinical Trial of TorreyPines Therapeutics Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
7. United Therapeutics to Announce 2008 Fourth Quarter and Annual Financial Results Before Market Open on Tuesday, February 17, 2009
8. Northwest Biotherapeutics Secures $700,000 Equity Financing
9. iCo Therapeutics Closes $1.3 Million Private Placement
10. Cell Therapeutics, Inc. (CTI) BIO CEO Presentation to be Webcast
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... USA (PRWEB) May 17, 2013 •    First ... Globes Certified for sustainability ,     New facility will ... , Syngenta unveiled its new ... at the company’s RTP Innovation Center. The first of ... researchers to simulate any agricultural climate and precisely measure ...
(Date:5/17/2013)... 17, 2013  Cellular Biomedicine Group (OTCQB: CBMG) ... of the total projected enrollment required for its ... preliminary efficacy of the medical technology haMPC (Human ... (KOA). To date the trial has had no ... Phase I open label clinical research trial for ...
(Date:5/17/2013)... , May 17, 2013 /PRNewswire-iReach/ -- Aridis ... been reached with Switzerland -based ... anti-infective human monoclonal antibody (mAb) products, and technologies. ... mAb products for treatment of infections by common ... Staphylococcus aureus , Pseudomonas aeruginosa , ...
(Date:5/17/2013)... Miami, FL (PRWEB) May 17, 2013 Men’s ... at La-roche Posay ) and has been known ... itself. Although some men may be far from puberty, other ... be clogging pores, causing breakouts, and threatening skin with unsightly ... with advice from Men’s Health on how to ...
Breaking Biology Technology:Syngenta Opens Unique $72 Million Advanced Crop Lab 2Syngenta Opens Unique $72 Million Advanced Crop Lab 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2
... MOORESVILLE, N.C., March 15, 2011 Approximately 50,000 ... to Tokushukai Hospital in Tokyo, Japan for ... crisis. This effort was facilitated by Dr. Alisa Suzuki ... a teaching facility of Harvard Medical School, in Boston, ...
... BETHLEHEM, PAA team of electrical engineers and chemists at ... demonstrating that plasmonic structures can slow down light waves ... that a rainbow of broadband light could be slowed ... been predicted in theoretical studies of metamaterials. The Lehigh ...
... CHICAGO, March 14, 2011 Argentum Medical, LLC today issued ... litigation versus Noble Biomaterials, Inc. "The most important ... our patents and it is business as usual for Argentum," ... "The case concerned non-patent issues and is currently being appealed. ...
Cached Biology Technology:50,000 Potassium Iodide Pills Donated to Japan 2Trapping a rainbow: Lehigh researchers slow broadband light waves with nanoplasmonic structures 2Argentum Medical Issues Response to Recent Decision in Litigation With Noble Biomaterials 2
(Date:5/19/2013)... a strain of electricity-producing bacteria that can grow using ... dioxide as its sole source of carbon. Researchers ... at the 113th General Meeting of the American Society ... current production solely on hydrogen," says Amit Kumar, a ... are part of the Lovley Lab Group at the ...
(Date:5/19/2013)... at the University of California, Davis have engineered a ... for light. They report their findings today at ... Microbiology. , "In this work, we used synthetic biology ... carbon dioxide and light energy for growth) cyanobacterial metabolism ... Jordan McEwen, the lead researcher on the study. ...
(Date:5/18/2013)... The AGA Research Foundation is honored to announce ... in Digestive Cancer, which will support Andrew D. Rhim, ... University of Pennsylvania, Philadelphia, as he furthers his research ... and cancer progression. , "The AGA Research Foundation is ... distinguished clinicians and AGA Legacy Society members," said Nicholas ...
Breaking Biology News(10 mins):AGA Research Foundation grant furthers digestive cancer research 2
... are not, are at more risk for depression than girls ... sociologists. "Parents often worry about overweight girls, mental ... have a healthy weight but perceive being overweight who are ... student in sociology and demography. In the past, researchers ...
... on the alert for signs of Phytophthora blight ... in 1999, causing up to 100 percent crop losses in ... to this industry, it is the most devastating and it,s ... Illinois Extension specialist in fruit and vegetable pathology, said, "An ...
... to $19 million from the U.S. Department of Energy and NRG ... capture and storage demonstration project in southeast Texas. The project ... carbon dioxide (CO 2 ) from a coal-fired power plant. ... Texas, and one of only a handful in the world, to ...
Cached Biology News:The image in the mirror and the number on the scale both count 2The image in the mirror and the number on the scale both count 3Illinois pumpkin fields face cunning opponent 2University receives $19 million to monitor carbon storage project 2University receives $19 million to monitor carbon storage project 3
... counts, similar to an infrared beam break system, ... at once, in two frames of reference, recording ... group at once, and allow social interaction as ... variety of other spatial behavior situations, including output ...
... Object Records behavior directed toward examining a novel ... a family of instruments all built around a ... and that can track two fields at once ... automatically extracts animal positions and records them, but ...
... Last innovation from Magnetofection technology, SilenceMag ... system available. Simple, rapid and easy ... and non toxic. Specifically designed for ... silencing at very low doses of ...
... Last innovation from Magnetofection technology, ... delivery system available. Simple, rapid and ... compatible and non toxic. Specifically designed ... gene silencing at very low doses ...
Biology Products: